Premium
AMANTADINE HYDROCHLORIDE IN THE TREATMENT OF PARKINSON'S DISEASE
Author(s) -
Gilligan Bernard S.,
Veale John,
Wodak Jack
Publication year - 1970
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1970.tb50241.x
Subject(s) - amantadine , placebo , medicine , hydrochloride , parkinson's disease , drug , disease , pharmacology , anesthesia , chemistry , alternative medicine , pathology , organic chemistry
A double‐blind control trial of amantadine hydrochloride in a dosage of 200 mg per day, and placebo, each given for three weeks to 33 patients suffering from Parkinson's disease, confirms the results of previous studies, which showed that amantadine hydrochloride is a well‐tolerated drug and has a beneficial effect of varying degree on the disease. In a smaller separate group of patients treated for several months, the effect of the drug was maintained. Amantadine appears to be a useful addition to the current range of antiparkinsonian drugs.